Q1 EPS Estimate for Stoke Therapeutics Lifted by Analyst

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Investment analysts at Wedbush boosted their Q1 2025 earnings estimates for shares of Stoke Therapeutics in a report issued on Tuesday, March 18th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.57) per share for the quarter, up from their prior estimate of ($0.58). The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics' Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.37) EPS, FY2026 earnings at ($3.02) EPS, FY2027 earnings at ($3.13) EPS, FY2028 earnings at ($2.69) EPS and FY2029 earnings at ($2.01) EPS.

A number of other research analysts have also recently issued reports on STOK. Needham & Company LLC restated a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, March 18th. Chardan Capital reiterated a "buy" rating and set a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday, March 19th. Cantor Fitzgerald reissued an "overweight" rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $47.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $23.00.

Remove Ads

Stoke Therapeutics Stock Performance

STOK traded down $0.55 during midday trading on Friday, reaching $7.74. 1,074,611 shares of the company were exchanged, compared to its average volume of 839,762. Stoke Therapeutics has a one year low of $6.29 and a one year high of $17.58. The stock has a market capitalization of $418.56 million, a P/E ratio of -3.69 and a beta of 0.99. The stock's 50-day simple moving average is $9.46 and its 200 day simple moving average is $11.35.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million.

Insider Activity

In other news, insider Barry Ticho sold 3,884 shares of the business's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares of the company's stock, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock valued at $143,332 over the last ninety days. 11.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. RTW Investments LP increased its stake in shares of Stoke Therapeutics by 10.1% in the fourth quarter. RTW Investments LP now owns 5,123,525 shares of the company's stock valued at $56,512,000 after buying an additional 471,240 shares during the period. Baker BROS. Advisors LP increased its holdings in Stoke Therapeutics by 6.1% in the fourth quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company's stock valued at $51,111,000 after purchasing an additional 265,395 shares during the period. Toronto Dominion Bank bought a new position in Stoke Therapeutics during the 4th quarter worth $35,001,000. State Street Corp lifted its holdings in Stoke Therapeutics by 8.6% during the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company's stock worth $21,248,000 after buying an additional 137,145 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in shares of Stoke Therapeutics by 2.9% in the 4th quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company's stock valued at $14,901,000 after buying an additional 38,446 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.